NCT03789240 2026-03-03
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT06865677 2026-01-21
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05009979 2025-08-28
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05012098 2025-08-08
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001337 2025-06-22
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03824535 2025-04-09
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Stanford University
Phase 2 Completed
NCT03089606 2023-11-15
Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03125629 2021-04-09
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
Stanford University
Phase 2 Completed
NCT02611882 2020-12-22
PSMA PET
University of California, San Francisco
Phase 2 Completed
NCT01395030 2018-09-26
PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Queen's Medical Center
Phase 2 Completed